Key Players
Competitive Landscape
Four business models compete in the NGS-based RNA sequencing market: integrated short-read platform companies, long-read sequencing specialists, single-cell workflow developers and sequencing-service providers. Laboratories compare library reproducibility with transcript resolution and dependable technical support across research sites.
Investment has moved in two directions since 2025 toward very large single-cell datasets and workflows that recover transcriptome information from preserved tissue. In July 2026, Illumina expanded its Billion Cell Atlas alliance with more than 350 million cells sequenced and over six petabytes of data generated. In March 2026, Parse Biosciences began shipping whole-transcriptome single-cell kits for FFPE tissue. Laboratories now prioritize sample compatibility with data scale and integrated analysis ahead of unit-price comparisons.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In July 2026, Illumina added three members to its Billion Cell Atlas alliance with more than 350 million cells sequenced and over six petabytes of data generated. | Drug developers need perturbation data at scale to test targets and disease mechanisms. | Single-cell RNA sequencing is becoming shared data infrastructure for model development. | Sequencing runs, library inputs and cloud analysis support recurring revenue around atlas programs. |
| In March 2026, Parse Biosciences began shipping Evercode whole-transcriptome single-cell kits for FFPE tissue. | Cancer and translational laboratories need archived tissue to remain usable for cell-level expression studies. | Single-cell workflows are extending beyond fresh or frozen samples into routine biobank material. | Kits, preparation support and analysis services address retrospective cohorts held in pathology archives. |
| In April 2026, 10x Genomics introduced Atera for spatial whole-transcriptome analysis with single-cell sensitivity and expected shipments during the second half of 2026. | Research centers need spatial expression data without losing cell-level sensitivity across tissue sections. | Spatial transcriptomics and sequencing workflows are moving toward integrated high-throughput platforms. | Instrument placement, consumables and analysis software serve tissue-mapping programs across oncology and biology. |
Takara Bio competes through low-input and single-cell library preparation, although no dated exact-market development was found for the company between January 2025 and July 2026.
Source: Future Market Insights, NGS-Based RNA Sequencing Market and Single-Cell Analysis System Market Reports, 2026-2036.
Illumina and QIAGEN through Parse Biosciences cover high-throughput sequencing, single-cell barcoding and preserved-tissue workflows across research laboratories. Roche and 10x Genomics add single-molecule and spatial platforms that broaden transcriptome analysis across tissue studies. Illumina also reports an ISO 13485:2016 multisite certificate across San Diego, Hayward, Madison, Cambridge and Eindhoven.
Who leads the NGS-based RNA sequencing market?
Illumina leads the approved company set with 24.1% share in 2026 and expanded its Billion Cell Atlas alliance in July 2026 after sequencing more than 350 million cells. QIAGEN competes through Parse Biosciences, which began shipping whole-transcriptome single-cell kits for FFPE samples in March 2026.
Which suppliers have documented qualification or quality approvals?
Illumina reports ISO 13485:2016 certification for a multisite quality system covering San Diego, Hayward, Madison, Cambridge and Eindhoven. Thermo Fisher Scientific lists ISO 13485:2016 for Life Technologies facilities in Frederick within Maryland that cover molecular biology reagents, diagnostics software and analytical instrument systems.
Which companies provide single-cell and long-read RNA sequencing workflows?
QIAGEN's Parse Biosciences unit and 10x Genomics provide single-cell transcriptomics workflows for suspension samples, preserved tissue and spatial analysis. PacBio and Oxford Nanopore Technologies provide long-read transcriptomics routes for full-length isoforms or native RNA analysis across research programs.
Which suppliers serve North America and Europe?
Illumina, Thermo Fisher Scientific, QIAGEN, PacBio and 10x Genomics serve North America and Europe through direct commercial operations. Oxford Nanopore serves both regions from its United Kingdom base and established international commercial network. Takara Bio supports those regions through North American and European subsidiaries serving research laboratories.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Illumina, Inc. | Global | Short-read RNA sequencing and large-scale single-cell workflows; Billion Cell Atlas expanded in July 2026. |
| Thermo Fisher Scientific Inc. | Global | Sequencing instruments, RNA library workflows, nucleic-acid preparation and bioinformatics across research laboratories. |
| QIAGEN N.V. / Parse Biosciences | Global | Instrument-free single-cell barcoding, FFPE whole-transcriptome kits and analysis software; kits shipped in March 2026. |
| 10x Genomics, Inc. | Global | Single-cell and spatial transcriptomics platforms; Atera introduced in April 2026 for spatial whole-transcriptome analysis. |
| Pacific Biosciences | Global | HiFi long-read sequencing and Kinnex full-length RNA workflows for isoform analysis. |
| Oxford Nanopore Technologies | Global | cDNA and direct RNA sequencing for native-RNA analysis and modification assessment. |
| BGI Genomics | Global service network | Large-scale single-cell profiling and sequencing services for international research programs. |
| Agilent Technologies | Global | Combined DNA/RNA cancer research assays with automated preparation and analysis support; SureSelect Cancer Pan Heme introduced in April 2025. |
| Takara Bio Inc. | Japan, North America and Europe | Low-input and single-cell RNA library preparation with research reagents and technical support. |
| Roche Diagnostics | Global | SBX single-molecule sequencing for bulk RNA, single-cell RNA and spatial research; AXELIOS 1 launched in June 2026. |
Research Methodology
The companies in this section illustrate how the NGS-based RNA sequencing market is structured and do not form a ranking. A company appears in the overview once current public evidence confirms sequencing platforms, RNA library preparation, single-cell or spatial transcriptomics, analysis software or sequencing services. Evidence includes official company filings and announcements alongside quality certificates and current corporate reports from the review period. Site registrations are attributed to the named entity or facility instead of the wider corporate group. The 24.1% Illumina share and every segment share cited here are FMI estimates for 2026.
